Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest Allon Stories

2012-06-21 02:26:45

VANCOUVER, June 21, 2012 /PRNewswire/ - Allon Therapeutics Inc. TSX: NPC President and CEO Gordon McCauley is presenting an update of the Company's progress today at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade in Toronto. McCauley's presentation will include an update of the Company's programs, including the pivotal clinical trial evaluating its lead neuroprotective drug candidate, davunetide, as a potential treatment for PSP, a rapidly...

2012-05-30 02:26:03

VANCOUVER, May 30, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley is presenting an update of the Company's progress today at the BioFinance 2012 investor conference in Toronto. McCauley's presentation will include the latest review of the Company's on-going pivotal trial in progressive supranuclear palsy (PSP) by the independent Data Safety Monitoring Board (DSMB) and its recommendation to continue the trial. The DSMB recently completed its...

2012-05-02 02:27:54

VANCOUVER, May 2, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that it has completed the previously announced brokered private placement equity offering resulting in gross proceeds of $10 million as more particularly described below. Gordon McCauley, President and CEO of Allon Therapeutics said Allon remains on track to complete patient dosing in its pivotal trial in progressive supranuclear palsy (PSP) and release top-line data by late 2012. "We have...

2012-04-16 02:28:12

VANCOUVER, April 16, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that  it plans to complete a brokered private placement equity offering to raise approximately $10.0 million. The placement is substantially committed. The proceeds will be used for the completion of Allon's ongoing pivotal clinical trial, testing lead product candidate davunetide as a potential treatment for progressive supranuclear palsy (PSP) and general corporate purposes.  Allon...